MENU

3D-Micro Tissues in Translational Toxicology and Disease Modelling

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Chief Scientific Officer, InSphero AG
    Biography
      Armin Wolf is Chief Scientific Officer at InSphero AG in ZH, Switzerland and Professor of Toxicology at the Technical University of Kaiserslautern, Germany. He is an accomplished pharmaceutical R&D executive and board-certified toxicologist with more than 30 years cumulative experience at Novartis and Janssen. Armin offers a first-hand perspective on the challenges facing the pharmaceutical industry

    Abstract

    3D liver microtissues (also known as 3D spheroids) have the potential to positively impact drug development workflows, particularly when applied to safety assessment and drug discovery processes. These 3D in vitro liver models, which can be engineered to mimic healthy and diseased biology in human or model organisms (e.g., monkey, dog, and rat),  have been proven to be powerful tools for fulfilling the demands of modern toxicology programs, both in terms of providing translational safety insights and pushing the bench closer to the patient bedside.
     
    In this lecture, you will learn:
     
    1. Practical liver toxicology applications for 3D human liver microtissues, from safety testing to complex disease modeling, using non-alcoholic steatohepatitis (NASH) as an example.  
    2. Considerations for adapting existing protocols to leverage 3D liver microtissues and upgrade your tox toolbox for investigating specific scientific questions related to drug induced liver injury (DILI) and drug efficacy testing of new drug candidates, such as promising therapies currently under development for NASH —all with a high degree of flexibility.
    3. Guidelines for adopting 3D human liver microtissues for use in high-throughput applications, which require uniform spheroid quality, functional robustness, assay scalability, and reproducibility of results.
    4. How 3D cell technology is evolving into an investigative tool that will meet the challenges of the next generation of therapeutic modalities.

     


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 16, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    Loading Comments...
    Show Resources
    Attendees
    • See more